A Novel C5a-neutralizing Mirror-image (l-)Aptamer Prevents Organ Failure and Improves Survival in Experimental Sepsis

Complement factor C5a is a potent proinflammatory mediator that contributes to the pathogenesis of numerous inflammatory diseases. Here, we describe the discovery of NOX-D20, a PEGylated biostable mirror-image mixed (l-)RNA/DNA aptamer (Spiegelmer) that binds to mouse and human C5a with picomolar affinity. In vitro, NOX-D20 inhibited C5a-induced chemotaxis of a CD88-expressing cell line and efficiently antagonized the activation of primary human polymorphonuclear leukocytes (PMN) by C5a. Binding of NOX-D20 to the C5a moiety of human C5 did not interfere with the formation of the terminal membrane attack complex (MAC). In sepsis, for which a specific interventional therapy is currently lacking, complement activation and elevated levels of C5a are suggested to contribute to multiorgan failure and mortality. In the model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), NOX-D20 attenuated inflammation and organ damage, prevented the breakdown of the vascular endothelial barrier, and improved survival. Our study suggests NOX-D20 as a new therapeutic candidate for the treatment of sepsis.

[1]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[2]  L. Birnbaumer,et al.  Macrophages Induce the Inflammatory Response in the Pulmonary Arthus Reaction through Gαi2 Activation That Controls C5aR and Fc Receptor Cooperation1 , 2005, The Journal of Immunology.

[3]  Ronny Lorenz,et al.  The Vienna RNA Websuite , 2008, Nucleic Acids Res..

[4]  A. Blom,et al.  Early Complementopathy After Multiple Injuries in Humans , 2012, Shock.

[5]  R A Bendele,et al.  Derivation of RNA aptamer inhibitors of human complement C5. , 1999, Immunopharmacology.

[6]  J. V. D. van der Meer,et al.  Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. , 2003, Blood.

[7]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[8]  C. Mackay,et al.  Functional roles for C5a receptors in sepsis , 2008, Nature Medicine.

[9]  N. Janjić,et al.  Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.

[10]  C. Gerard,et al.  The chemotactic receptor for human C5a anaphylatoxin , 1991, Nature.

[11]  S. Klußmann,et al.  Targeting complement component 5a promotes vascular integrity and limits airway remodeling , 2013, Proceedings of the National Academy of Sciences.

[12]  V. Erdmann,et al.  Mirror-image RNA that binds D-adenosine , 1996, Nature Biotechnology.

[13]  A. Schmaier,et al.  Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. , 2002, The American journal of pathology.

[14]  T. van der Poll,et al.  Peritoneal macrophages are important for the early containment of Enterococcus faecium peritonitis in mice , 2009, Innate immunity.

[15]  P. Ward,et al.  Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. , 2012, Advances in experimental medicine and biology.

[16]  S. Klußmann,et al.  Polyetheylenimine-Polyplexes of Spiegelmer NOX-A50 Directed against Intracellular High Mobility Group Protein A1 (HMGA1) Reduce Tumor Growth in Vivo* , 2010, The Journal of Biological Chemistry.

[17]  P. Monk,et al.  The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74 * , 2002, The Journal of Biological Chemistry.

[18]  John D Lambris,et al.  Protection of innate immunity by C5aR antagonist in septic mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  D. Rittirsch,et al.  Immunodesign of experimental sepsis by cecal ligation and puncture , 2008, Nature Protocols.

[20]  S. Sell,et al.  The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. , 2013, Blood.

[21]  Ralph Weissleder,et al.  Arthritis critically dependent on innate immune system players. , 2002, Immunity.

[22]  D. Fry.  Article Commentary: Sepsis, Systemic Inflammatory Response, and Multiple Organ Dysfunction: The Mystery Continues , 2012, The American surgeon.

[23]  Kutty Selva Nandakumar,et al.  Inhibiting the C5-C5a receptor axis. , 2011, Molecular immunology.

[24]  K. Langa,et al.  Long-term cognitive impairment and functional disability among survivors of severe sepsis. , 2010, JAMA.

[25]  P. Monk,et al.  International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors , 2013 .

[26]  K. Messlinger,et al.  Inhibition of stimulated meningeal blood flow by a calcitonin gene‐related peptide binding mirror‐image RNA oligonucleotide , 2006, British journal of pharmacology.

[27]  P. Monk,et al.  Correction to “International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors” , 2014, Pharmacological Reviews.

[28]  Anna J. Strachan,et al.  Inhibition of immune‐complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist , 2002, British journal of pharmacology.

[29]  S. Klußmann,et al.  Identification and characterisation of C5a-inhibiting biostable aptamers , 2010 .

[30]  P. Ward,et al.  Protective effects of C5a blockade in sepsis , 1999, Nature Medicine.

[31]  J. V. Sarma,et al.  Complement-Induced Impairment of Innate Immunity During Sepsis1 , 2002, The Journal of Immunology.

[32]  J. Solomkin,et al.  Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. , 1981, Surgery.

[33]  P. Ward,et al.  Manipulation of the Complement System for Benefit in Sepsis , 2012, Critical care research and practice.

[34]  H. Pavenstädt,et al.  The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis , 2011, Critical care.

[35]  John D Lambris,et al.  C5a and TNF-α Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome1 , 2008, The Journal of Immunology.

[36]  S. Klußmann,et al.  Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First‐in‐Class Mirror‐Image Oligonucleotide Inhibitor of CXCL12 , 2013, Clinical pharmacology and therapeutics.

[37]  R. Boisgard,et al.  In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  G. Kumar,et al.  Nationwide trends of severe sepsis in the 21st century (2000-2007). , 2011, Chest.

[39]  Hongjun Bai,et al.  New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. , 2013, Immunobiology.

[40]  M. J. Evans,et al.  In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. , 1995, Molecular immunology.

[41]  J. V. Sarma,et al.  Functions of the complement components C3 and C5 during sepsis , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  F. Tacke,et al.  High C5a levels are associated with increased mortality in sepsis patients--no enhancing effect by actin-free Gc-globulin. , 2008, Clinical biochemistry.

[43]  J. Hamer,et al.  In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata* , 2007, Journal of Biological Chemistry.

[44]  T. Luedde,et al.  Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury , 2011, Gut.

[45]  S. Klußmann,et al.  RNA Aptamers and Spiegelmers: Synthesis, Purification, and Post‐Synthetic PEG Conjugation , 2011, Current protocols in nucleic acid chemistry.

[46]  R. Rieben,et al.  Role of complement and perspectives for intervention in ischemia-reperfusion damage , 2012, Annals of medicine.

[47]  P. Pronovost,et al.  Long-term mortality and quality of life in sepsis: A systematic review* , 2010, Critical care medicine.

[48]  S. Sell,et al.  A Mixed Mirror-image DNA/RNA Aptamer Inhibits Glucagon and Acutely Improves Glucose Tolerance in Models of Type 1 and Type 2 Diabetes , 2013, The Journal of Biological Chemistry.

[49]  S. Klußmann,et al.  An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Schmidt,et al.  C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. , 2002, The Journal of clinical investigation.

[51]  P. Ward,et al.  Role of C5a in Multiorgan Failure During Sepsis1 , 2001, The Journal of Immunology.